Five Oceans Advisors Makes New $220,000 Investment in GSK plc (NYSE:GSK)

Five Oceans Advisors acquired a new stake in GSK plc (NYSE:GSK) in the 1st quarter, according to the company in its most recent filing with the SEC. The firm acquired 5,683 shares of the pharmaceutical company’s stock, valued at approximately $220,000.

Several other hedge funds have also recently modified their holdings of the company. Brighton Jones LLC purchased a new stake in shares of GSK during the fourth quarter valued at approximately $528,000. Savant Capital LLC increased its position in shares of GSK by 44.5% during the 4th quarter. Savant Capital LLC now owns 8,126 shares of the pharmaceutical company’s stock valued at $275,000 after purchasing an additional 2,504 shares during the last quarter. Strategic Financial Concepts LLC purchased a new stake in shares of GSK during the 4th quarter valued at $4,033,000. Allworth Financial LP raised its stake in shares of GSK by 175.0% during the 4th quarter. Allworth Financial LP now owns 7,859 shares of the pharmaceutical company’s stock worth $263,000 after purchasing an additional 5,001 shares during the period. Finally, Csenge Advisory Group boosted its holdings in shares of GSK by 13.7% in the 4th quarter. Csenge Advisory Group now owns 20,141 shares of the pharmaceutical company’s stock worth $681,000 after buying an additional 2,423 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Stock Performance

NYSE GSK opened at $40.50 on Tuesday. The firm has a market cap of $83.00 billion, a P/E ratio of 25.47, a price-to-earnings-growth ratio of 1.12 and a beta of 0.52. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The company’s 50 day moving average is $38.22 and its 200-day moving average is $36.73. GSK plc has a 12-month low of $31.72 and a 12-month high of $44.67.

GSK (NYSE:GSK) last released its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, beating analysts’ consensus estimates of $1.08 by $0.05. The business had revenue of $10.06 billion during the quarter, compared to analyst estimates of $7.52 billion. GSK had a net margin of 8.13% and a return on equity of 48.59%. GSK’s revenue was up 2.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.43 EPS. Sell-side analysts predict that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be issued a dividend of $0.4216 per share. This is a boost from GSK’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, May 16th. This represents a $1.69 dividend on an annualized basis and a yield of 4.16%. GSK’s dividend payout ratio is 86.60%.

Wall Street Analyst Weigh In

GSK has been the subject of a number of research analyst reports. Wall Street Zen downgraded shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, May 30th. Berenberg Bank restated a “hold” rating on shares of GSK in a research note on Tuesday, June 3rd. Hsbc Global Res upgraded GSK to a “strong sell” rating in a research note on Monday, April 28th. Finally, BNP Paribas started coverage on GSK in a report on Tuesday, April 15th. They set a “neutral” rating and a $35.25 price objective for the company. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, GSK has a consensus rating of “Hold” and a consensus target price of $37.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.